[Expression of glucocorticoid receptor in prostate cancer and its clinical significance]

Zhonghua Nan Ke Xue. 2022 Mar;28(3):211-216.
[Article in Chinese]

Abstract

Objective: To investigate the expression of glucocorticoid receptor (GR) in the PCa tissue and its correlation with the clinicopathological characteristics and prognosis of PCa.

Methods: Using immunohistochemical staining, we determined the expression of GR in the PCa tissue and analyzed its correlation with the clininicopathological features and prognosis of the malignancy.

Results: The positive expression of GR in the PCa tissue was 64%, of which the strongly positive rate was 34.7%. The GR expression was positively correlated with preoperative androgen-deprivation therapy (ADT) (χ2 = 22.307, P < 0.01), Gleason grades (χ2 = 16.534, P = 0.002) and clinical stages of the tumor (χ2 = 9.969, P = 0.041). Kaplan-Meier analysis showed that the GR expression was correlated not with the overall survival (P = 0.156), but with the PSA progression-free survival rate of the PCa patients (P = 0.042), with a shorter PSA progression-free survival time in those with a higher GR expression. Multivariate COX regression analysis revealed that the expression of GR was not an independent prognostic factor for PSA progression-free survival of the PCa patients.

Conclusion: The expression of GR is related with preoperative ADT, and closely with the biological behavior of the malignancy and treatment resistance of the patients. GR is expected to be a new effective therapeutic target and a prognostic biomarker for PCa.

Keywords: prostate cancer; glucocorticoid receptor; immunohistochemistry; prognosis.

Publication types

  • English Abstract

MeSH terms

  • Androgen Antagonists / therapeutic use
  • Clinical Relevance
  • Humans
  • Male
  • Prognosis
  • Prostate-Specific Antigen
  • Prostatic Neoplasms* / pathology
  • Receptors, Glucocorticoid / therapeutic use

Substances

  • Prostate-Specific Antigen
  • Receptors, Glucocorticoid
  • Androgen Antagonists